Acute neural effects of the mood stabiliser lamotrigine on emotional processing in healthy volunteers: a randomised control trial

• Published in: Translational psychiatry Vol. 14; no. 1; pp. 211 - 9
• Main Authors: Martens, Marieke A. G., Zghoul, Tarek, Watson, Evelyn, Rieger, Sebastian W., Capitão, Liliana P., Harmer, Catherine J.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 27.05.2024; Nature Publishing Group
• Subjects: 631/477/2811; 692/699/476/1333; Adult; Amygdala - diagnostic imaging; Amygdala - drug effects; Antidepressants; Antimanic Agents - administration & dosage; Antimanic Agents - pharmacology; Behavioral Sciences; Biological Psychology; Bipolar disorder; Brain - diagnostic imaging; Brain - drug effects; Brain research; Double-Blind Method; Drug dosages; Emotions - drug effects; Facial Expression; Facial Recognition - drug effects; Female; Gyrus Cinguli - diagnostic imaging; Gyrus Cinguli - drug effects; Healthy Volunteers; Humans; Information processing; Lamotrigine - administration & dosage; Lamotrigine - pharmacology; Magnetic Resonance Imaging; Male; Medicine; Medicine & Public Health; Mental depression; Neuropsychology; Neurosciences; Pharmacotherapy; Psychiatry; Psychotropic drugs; Questionnaires; Sex discrimination; Triazines - administration & dosage; Triazines - pharmacology; Young Adult
• ISSN: 2158-3188; 2158-3188
• DOI: 10.1038/s41398-024-02944-6

Lamotrigine is an effective mood stabiliser, largely used for the management and prevention of depression in bipolar disorder. The neuropsychological mechanisms by which lamotrigine acts to relieve symptoms as well as its neural effects on emotional processing remain unclear. The primary objective of this current study was to investigate the impact of an acute dose of lamotrigine on the neural response to a well-characterised fMRI task probing implicit emotional processing relevant to negative bias. 31 healthy participants were administered either a single dose of lamotrigine (300 mg, n  = 14) or placebo ( n  = 17) in a randomized, double-blind design. Inside the 3 T MRI scanner, participants completed a covert emotional faces gender discrimination task. Brain activations showing significant group differences were identified using voxel-wise general linear model (GLM) nonparametric permutation testing, with threshold free cluster enhancement (TFCE) and a family wise error (FWE)-corrected cluster significance threshold of p  < 0.05. Participants receiving lamotrigine were more accurate at identifying the gender of fearful (but not happy or angry) faces. A network of regions associated with emotional processing, including amygdala, insula, and the anterior cingulate cortex (ACC), was significantly less activated in the lamotrigine group compared to the placebo group across emotional facial expressions. A single dose of lamotrigine reduced activation in limbic areas in response to faces with both positive and negative expressions, suggesting a valence-independent effect. However, at a behavioural level lamotrigine appeared to reduce the distracting effect of fear on face discrimination. Such effects may be relevant to the mood stabilisation effects of lamotrigine.